Tag: KDC-MN-194

  • Lixisenatide

    GLP-1 receptor agonist

    A daily-dosing GLP-1 receptor agonist FDA-approved 2016 (Adlyxin) for T2DM, structurally derived from exenatide.

    Abstract

    Lixisenatide (Adlyxin, Lyxumia; CAS 320367-13-3; molecular weight 4858.49) is a 44-amino-acid peptide GLP-1 receptor agonist developed by Sanofi and approved by the FDA in 2016 for T2DM. The compound is structurally derived from exenatide with a six-lysine C-terminal extension. Pharmacokinetics: plasma half-life ~3 hours; once-daily dosing.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.